Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
Entera Bio Ltd (NASDAQ: ENTX) will report its financial and business results for the year ended December 31, 2021, on March 8, 2022, at 6:30 AM EST. Following the results, a conference call will be held at 8:30 AM EST, where management will discuss the findings and take questions from participants. The company specializes in orally delivered large molecule therapeutics, focusing on conditions with significant unmet medical needs. Its lead candidates are EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in clinical development.
- Entera is advancing its lead candidates, EB613 and EB612, in clinical trials aimed at significant unmet medical needs.
- The company has established a collaboration with Amgen, enhancing its profile in the biopharmaceutical industry.
- None.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the 12 months ended December 31, 2021 on Tuesday, March 8, 2022 at 6:30 AM EST.
Entera’s management will host a conference call later that morning, Tuesday, March 8, at 8:30 AM EST to discuss the results for the year. A question-and-answer session will follow Entera’s remarks. To participate in the live call, please dial (877) 269-7756 (US) or (201) 689-7817 (international) or 1809406247 (Israel) and provide the conference ID “13727633” five to ten minutes before the start of the call.
To access a live audio webcast of the presentation on the “Investor Relations” page of Entera’s website, please click here. A replay of the webcast will be archived on Entera’s website for approximately 45 days following the presentation.
About Entera Bio
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
Investors:
Nicole Jones
CG Capital
404-736-3838
entx@cg.capital
FAQ
When will Entera Bio report its financial results for 2021?
What are the lead candidates for Entera Bio?
How can I access Entera Bio's conference call?
What technology does Entera Bio use for drug delivery?
